Latest Breaking News On - Interpace biosciences inc - Page 6 : comparemela.com
Interpace Biosciences Announces Path Forward in Letter to Shareholders Nasdaq:IDXG
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Interpace Biosciences Announces CFO Leadership Transition
February 04, 2021 16:42 ET | Source: Interpace Biosciences, Inc. Interpace Biosciences, Inc. UNITED STATES
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace’s Chief Financial Officer (“CFO”). Mr. Freeburg succeeds Fred Knechtel effective February 1, 2021.
Mr. Freeburg has been with Interpace since 2017 and brings over 20 years of financial and executive experience to his new role. As Chief Accounting Officer, he has led the company s Financial Reporting, Treasury, Financial Planning and Analysis (FP&A), Risk Management & Insurance and Corporate Development functions. Prior to Interpace, Tom served in senior finance roles at several other companies, whe
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
Interpace Biosciences, Inc.February 1, 2021 GMT
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts. Although some cysts may have no cancerous potential at all, other cysts carry up to a 48 percent chance of harboring invasive cancer, and surgery to remove them is often complex. Therefore, there is a need to develop additional tools to identify which pancreatic cysts may develop into cancer and which ones will not. In a recent, national multicenter study of patients undergoing surgery for pancreatic cysts, the Das-
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and .
Interpace Biosciences, Inc.January 20, 2021 GMT
Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior Year
Estimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 million
Realized Reimbursement on Higher ThyGeNEXT Pricing in January
Closed $5 Million Bridge Loan Agreement with Existing Private Equity Investors and terminated the SVB credit facility
Cash balance as of January 15, 2021 was $6.1 million net of restricted cash
Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET
vimarsana © 2020. All Rights Reserved.